VISUGLICAN*COLL 25D 40+2MG/ML
Treatment of toxic, allergic and spring conjunctivitis, with subacute and chronic progression.
Dosage and method of use
1-2 drops in the conjunctival fornix four times a day. Before use, make sure that the single-dose container is intact. Visuglican in single-dose container should only be used immediately after opening. Any residue must not be used. Avoid letting the tip of the container come into contact with your eye or any other surface.
Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1.
Irritation and burning phenomena have rarely been reported. In these cases it is advisable to suspend treatment. (see section 4.3) Very rarely, cases of corneal calcification have been reported associated with the use of phosphate-containing eye drops in patients with significantly damaged cornea. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https://www.aifa.gov.it/web/guest/content/segnalazioni-reazioni-avverse.
To be used under the direct supervision of a doctor. Do not use if the solution is not clear. Visuglican 10 ml bottle contains disodium phosphate 6.50 mg per 1 ml equivalent to 65 mg/10 ml, and monosodium phosphate 2 mg per 1 ml equivalent to 20 mg/10 ml. Visuglican single-dose contains disodium phosphate 8.12 mg per 1 ml equivalent to 4.06 mg/0.5 ml and monosodium phosphate 4.5 mg per 1 ml equivalent to 2.25 mg/0.5 ml.
Pregnancy and breastfeeding
As with any drug it is advisable, when possible, to avoid administration during the first trimester of pregnancy. If the use of this product is considered essential in a nursing mother, the patient should discontinue breast-feeding.
Expiration and conservation
Bottle: Store at a temperature not exceeding 25°C. Single dose: keep the product away from heat sources.
Interactions with other drugs
There are no known interactions with other drugs. However, additive effects are possible when Visuglican is administered simultaneously with H 2 antagonists (cimetidine) and corticosteroids.
No overdose phenomena have been reported.
100 ml of eye drops, solution contain: Active ingredients: Sodium Cromoglycate 4 g; Chlorphenamine maleate 0.2 g. For the full list of excipients, see section 6.1
Visuglican Eye Drops, solution in 10 ml bottle: 100 ml of eye drops contain: Sodium edetate; Disodium phosphate; Monosodium phosphate; Purified water. Visuglican Eye Drops, solution in single-dose containers: 100 ml of eye drops contain: Sodium edetate; Disodium phosphate; Monosodium phosphate; Water for injections.